Clene Inc., a biopharmaceutical company focused on neurodegenerative diseases, announced a $7 million underwritten offering of 1 million common shares at $7 each to a single investor. The funds will support general corporate expenses and advance the development of their lead drug candidate CNM-Au8®, including NDA preparation, ongoing and future clinical trials, manufacturing expansion, and early-stage research. The offering is expected to close around May 6, 2026. This capital raise is crucial for Clene's efforts to bring new treatments for diseases like ALS and multiple sclerosis to market.
Regentis Biomaterials shares surged over 500% intraday before falling 9.15% in after-hours trading following the company's announcement that it withdrew its Registration Statement for a public offering. The regenerative medicine firm decided not to p...
Elon Musk's SpaceX recently went public, raising questions about a potential IPO for its Starlink subsidiary. Data from prediction market Kalshi shows only a 7-10% chance of a Starlink IPO announcement before mid-2027. Meanwhile, Musk predicts SpaceX...
Goodfirms has published its 2026 rankings of top technology service providers across six categories: mobile app, software, web development, digital marketing, SEO, and AI development. These rankings are based on over 1.2 million verified client revie...
Alvotech announced a $152 million public offering and concurrent private placement of ordinary shares priced at $3.75 each. The public offering includes 22.7 million shares, with an option for underwriters to buy an additional 3.4 million shares. The...
Alvotech announced pricing and allocation of a $152 million public share offering in the US and a concurrent private placement in Europe at $3.75 per share. The company expects total proceeds up to $165 million if underwriters exercise their full opt...
